Oxford Immunotec Global (NASDAQ:OXFD) and Response Genetics (OTCMKTS:RGDXQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Risk & Volatility
Oxford Immunotec Global has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Comparatively, Response Genetics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500.
91.0% of Oxford Immunotec Global shares are held by institutional investors. 6.6% of Oxford Immunotec Global shares are held by insiders. Comparatively, 4.9% of Response Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Oxford Immunotec Global and Response Genetics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Oxford Immunotec Global||$103.08 million||3.72||-$32.88 million||($1.36)||-10.69|
Response Genetics has lower revenue, but higher earnings than Oxford Immunotec Global.
This is a summary of current ratings and recommmendations for Oxford Immunotec Global and Response Genetics, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Oxford Immunotec Global||0||0||2||0||3.00|
Oxford Immunotec Global presently has a consensus target price of $19.00, suggesting a potential upside of 30.67%. Given Oxford Immunotec Global’s higher probable upside, equities research analysts plainly believe Oxford Immunotec Global is more favorable than Response Genetics.
This table compares Oxford Immunotec Global and Response Genetics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Oxford Immunotec Global||-12.51%||-41.15%||-24.11%|
Oxford Immunotec Global beats Response Genetics on 6 of the 9 factors compared between the two stocks.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis. The company is also developing a range of assays for tick-borne diseases, such as lyme disease, as well as for use in screening blood for the parasite babesia microti that causes babesiosis; and T-SPOT.CMV test that measures the strength of a patient's cellular response to CMV infection. Oxford Immunotec Global PLC markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan, as well as through distributors in other parts of the world. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.
About Response Genetics
Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.